23 related articles for article (PubMed ID: 31538838)
1. XBP1 promotes NRAS
Salimi A; Schemionek-Reinders M; Huber M; Vieri M; Patterson JB; Alten J; Brümmendorf TH; Kharabi Masouleh B; Appelmann I
J Cell Mol Med; 2023 Nov; 27(21):3363-3377. PubMed ID: 37753803
[TBL] [Abstract][Full Text] [Related]
2. BCR::ABL1 fusion gene positive de novo acute myeloid leukemia with coexistence of NRAS mutation and presented with a peculiar CD58 positive immunophenotype.
Zhang X; Guo X
Cytometry B Clin Cytom; 2024 Mar; 106(2):146-148. PubMed ID: 37969054
[No Abstract] [Full Text] [Related]
3. Leukocytosis and Splenomegaly in a Neonate With NRAS Mutation.
Lucena MH; Balasundaram P; Carney M; Green E; Breilyn MS; Fuloria M
Clin Pediatr (Phila); 2024 May; 63(4):451-455. PubMed ID: 37264612
[No Abstract] [Full Text] [Related]
4. Primary myeloid sarcoma in an infant with an NRAS mutation.
Kamat A; Opipari V; Habiger C; Jasty R; Mody R; Sedig L
Pediatr Blood Cancer; 2024 Jun; 71(6):e30946. PubMed ID: 38462746
[No Abstract] [Full Text] [Related]
5. A Review of Cancer Genetics and Genomics Studies in Africa.
Rotimi SO; Rotimi OA; Salhia B
Front Oncol; 2020; 10():606400. PubMed ID: 33659210
[TBL] [Abstract][Full Text] [Related]
6. Mutation in NRAS in familial Noonan syndrome--case report and review of the literature.
Ekvall S; Wilbe M; Dahlgren J; Legius E; van Haeringen A; Westphal O; Annerén G; Bondeson ML
BMC Med Genet; 2015 Oct; 16():95. PubMed ID: 26467218
[TBL] [Abstract][Full Text] [Related]
7. Common KRAS and NRAS gene mutations in sporadic colorectal cancer in Northeastern Iranian patients.
Hamzehzadeh L; Khadangi F; Ghayoor Karimiani E; Pasdar A; Kerachian MA
Curr Probl Cancer; 2018 Nov; 42(6):572-581. PubMed ID: 29921458
[TBL] [Abstract][Full Text] [Related]
8. [NRAS Gene Expression and Its Clinical Significance in Patients with Acute Myeloid Leukemia].
Li TT; Li J; Geng YH; Zhang F; Liu L; Yang YL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):76-81. PubMed ID: 32027256
[TBL] [Abstract][Full Text] [Related]
9. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
Lázár V
Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
[TBL] [Abstract][Full Text] [Related]
10. Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.
Xu J; Haigis KM; Firestone AJ; McNerney ME; Li Q; Davis E; Chen SC; Nakitandwe J; Downing J; Jacks T; Le Beau MM; Shannon K
Cancer Discov; 2013 Sep; 3(9):993-1001. PubMed ID: 23733505
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
[TBL] [Abstract][Full Text] [Related]
12. Detection of
Anyanwu NCJ; Ella EE; Aminu M; Kazeem HM
J Immunoassay Immunochem; 2019; 40(6):605-616. PubMed ID: 31538838
[TBL] [Abstract][Full Text] [Related]
13. Treatment of NRAS-mutant melanoma.
Johnson DB; Puzanov I
Curr Treat Options Oncol; 2015 Apr; 16(4):15. PubMed ID: 25796376
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
